ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression

Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ). Upregulation of A disintegrin and metalloproteinases (ADAMs) is correlated to malignancy; however, whether ADAMs modulate TMZ sensitivity in GBM cells remains unclear. To explore the role of ADAMs in TMZ resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jen-Tsung, Lee, I-Neng, Huang, Cheng, Huang, Hsiu-Chen, Wu, Yu-Ping, Chong, Zhi-Yong, Chen, Jui-Chieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178422/
https://www.ncbi.nlm.nih.gov/pubmed/37175410
http://dx.doi.org/10.3390/ijms24097703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178422/
https://www.ncbi.nlm.nih.gov/pubmed/37175410
http://dx.doi.org/10.3390/ijms24097703

Ejemplares similares